Related Experiment Video
Updated: Jul 18, 2026
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
Metals and Alzheimer's disease.
1The Oxidation Disorders Laboratory, The Mental Health Research Institute, Parkville, Victoria, 3052, Australia. padlard@mhri.edu.au
Journal of Alzheimer'S Disease : JAD
|November 23, 2006
Summary
Metal ions like zinc and copper play a role in Alzheimer's disease (AD) pathogenesis by affecting amyloid beta (Abeta) and amyloid beta-protein precursor (AbetaPP) aggregation and oxidative stress. Dysregulated metal ion homeostasis may accelerate AD progression, suggesting new therapeutic targets.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Amyloid beta-protein precursor (AbetaPP) and amyloid beta (Abeta) are implicated in metal ion homeostasis.
- Metal ions (e.g., zinc, copper) interact with AbetaPP and Abeta.
- These interactions can potentiate Alzheimer's disease (AD) through protein aggregation and reactive oxygen species generation.
Purpose of the Study:
- To explore the role of metal ion homeostasis in Alzheimer's disease.
- To investigate the biochemical mechanisms linking metal ions to AD pathogenesis.
- To identify potential therapeutic targets for AD based on metal ion interactions.
Main Methods:
- Literature review and biochemical analysis of AbetaPP and Abeta interactions with metal ions.
- Examination of AD-related pathways affected by metal ions, including aggregation, oxidative stress, and secretase cleavage.
- Analysis of metal ion dysregulation in aging and AD.
Main Results:
- Metal ions interact with AbetaPP and Abeta, promoting aggregation and oxidative stress, key factors in AD.
- Metal ions influence other AD pathways, such as neurofibrillary tangle formation and AbetaPP secretase cleavage.
- Dysregulated metal ion homeostasis is observed in aging and AD, creating a pro-degenerative environment.
Conclusions:
- Metal ion dyshomeostasis is a significant factor in Alzheimer's disease development and progression.
- Interactions between metal ions and AbetaPP/Abeta offer a promising biochemical avenue for novel therapeutic interventions.
- Targeting metal ion homeostasis may provide a new strategy for treating Alzheimer's disease.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:23Role of Neurotransmitters in Memory
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is critical for...